Antibody depletion of CD4+ T cells did not decrease the efficacy of MSC-CD3-CD40L therapy (Figure 2A), whereas depletion of CD8+ T cells led to a complete loss of tumor control in both MC38 (Figure 2B) and CT26 (Supplemental Figure 2A). This evidence concerns the gene CD8A and neoplasm.